Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS)

Benedetto Vitiello*, Paul Rohde, Susan Silva, Karen Wells, Charles Casat, Bruce Waslick, Anne Simons, Mark Reinecke, Elizabeth Weller, Christopher Kratochvil, John Walkup, Sanjeev Pathak, Michele Robins, John March

*Corresponding author for this work

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

OBJECTIVE: To test whether 12-week treatment of major depression improved the level of functioning, global health, and quality of life of adolescents. METHOD: The Treatment for Adolescents With Depression Study was a multisite, randomized clinical trial of fluoxetine, cognitive-behavioral therapy (CBT), their combination (COMB), or clinical management with placebo in 439 adolescents with major depression. Functioning was measured with the Children's Global Assessment Scale (CGAS), global health with the Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA), and quality of life with the Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q). Random-effects regression models were applied to the data. RESULTS: Compared with placebo, COMB was effective on the CGAS (p < .0001), HoNOSCA (p < .05), and PQ-LES-Q (p < .001), whereas fluoxetine was superior to placebo on the CGAS only (p < .05). COMB was superior to fluoxetine on the CGAS (p < .05) and PQ-LES-Q (p = .001). Fluoxetine was superior to CBT on the CGAS (p < .01). CBT monotherapy was not statistically different from the placebo group on any of the measures assessed. Treatment effects were mediated by improvement in depressive symptoms measured on the Child Depression Rating Scale-Revised. CONCLUSIONS: The combination of fluoxetine and CBT was effective in improving functioning, global health, and quality of life in depressed adolescents. Fluoxetine monotherapy improved functioning. Copyright 2006

Original languageEnglish (US)
Pages (from-to)1419-1426
Number of pages8
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume45
Issue number12
DOIs
StatePublished - Dec 1 2006

Fingerprint

Fluoxetine
Quality of Life
Depression
Cognitive Therapy
Placebos
Therapeutics
Pediatrics
Health
Randomized Controlled Trials
Global Health
Surveys and Questionnaires

Keywords

  • Depression
  • Functioning
  • Impairment
  • Treatment

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Cite this

Vitiello, Benedetto ; Rohde, Paul ; Silva, Susan ; Wells, Karen ; Casat, Charles ; Waslick, Bruce ; Simons, Anne ; Reinecke, Mark ; Weller, Elizabeth ; Kratochvil, Christopher ; Walkup, John ; Pathak, Sanjeev ; Robins, Michele ; March, John. / Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). In: Journal of the American Academy of Child and Adolescent Psychiatry. 2006 ; Vol. 45, No. 12. pp. 1419-1426.
@article{654983f905a94ae282df962672fa214a,
title = "Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS)",
abstract = "OBJECTIVE: To test whether 12-week treatment of major depression improved the level of functioning, global health, and quality of life of adolescents. METHOD: The Treatment for Adolescents With Depression Study was a multisite, randomized clinical trial of fluoxetine, cognitive-behavioral therapy (CBT), their combination (COMB), or clinical management with placebo in 439 adolescents with major depression. Functioning was measured with the Children's Global Assessment Scale (CGAS), global health with the Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA), and quality of life with the Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q). Random-effects regression models were applied to the data. RESULTS: Compared with placebo, COMB was effective on the CGAS (p < .0001), HoNOSCA (p < .05), and PQ-LES-Q (p < .001), whereas fluoxetine was superior to placebo on the CGAS only (p < .05). COMB was superior to fluoxetine on the CGAS (p < .05) and PQ-LES-Q (p = .001). Fluoxetine was superior to CBT on the CGAS (p < .01). CBT monotherapy was not statistically different from the placebo group on any of the measures assessed. Treatment effects were mediated by improvement in depressive symptoms measured on the Child Depression Rating Scale-Revised. CONCLUSIONS: The combination of fluoxetine and CBT was effective in improving functioning, global health, and quality of life in depressed adolescents. Fluoxetine monotherapy improved functioning. Copyright 2006",
keywords = "Depression, Functioning, Impairment, Treatment",
author = "Benedetto Vitiello and Paul Rohde and Susan Silva and Karen Wells and Charles Casat and Bruce Waslick and Anne Simons and Mark Reinecke and Elizabeth Weller and Christopher Kratochvil and John Walkup and Sanjeev Pathak and Michele Robins and John March",
year = "2006",
month = "12",
day = "1",
doi = "10.1097/01.chi.0000242229.52646.6e",
language = "English (US)",
volume = "45",
pages = "1419--1426",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "12",

}

Vitiello, B, Rohde, P, Silva, S, Wells, K, Casat, C, Waslick, B, Simons, A, Reinecke, M, Weller, E, Kratochvil, C, Walkup, J, Pathak, S, Robins, M & March, J 2006, 'Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS)', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 45, no. 12, pp. 1419-1426. https://doi.org/10.1097/01.chi.0000242229.52646.6e

Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). / Vitiello, Benedetto; Rohde, Paul; Silva, Susan; Wells, Karen; Casat, Charles; Waslick, Bruce; Simons, Anne; Reinecke, Mark; Weller, Elizabeth; Kratochvil, Christopher; Walkup, John; Pathak, Sanjeev; Robins, Michele; March, John.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 45, No. 12, 01.12.2006, p. 1419-1426.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS)

AU - Vitiello, Benedetto

AU - Rohde, Paul

AU - Silva, Susan

AU - Wells, Karen

AU - Casat, Charles

AU - Waslick, Bruce

AU - Simons, Anne

AU - Reinecke, Mark

AU - Weller, Elizabeth

AU - Kratochvil, Christopher

AU - Walkup, John

AU - Pathak, Sanjeev

AU - Robins, Michele

AU - March, John

PY - 2006/12/1

Y1 - 2006/12/1

N2 - OBJECTIVE: To test whether 12-week treatment of major depression improved the level of functioning, global health, and quality of life of adolescents. METHOD: The Treatment for Adolescents With Depression Study was a multisite, randomized clinical trial of fluoxetine, cognitive-behavioral therapy (CBT), their combination (COMB), or clinical management with placebo in 439 adolescents with major depression. Functioning was measured with the Children's Global Assessment Scale (CGAS), global health with the Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA), and quality of life with the Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q). Random-effects regression models were applied to the data. RESULTS: Compared with placebo, COMB was effective on the CGAS (p < .0001), HoNOSCA (p < .05), and PQ-LES-Q (p < .001), whereas fluoxetine was superior to placebo on the CGAS only (p < .05). COMB was superior to fluoxetine on the CGAS (p < .05) and PQ-LES-Q (p = .001). Fluoxetine was superior to CBT on the CGAS (p < .01). CBT monotherapy was not statistically different from the placebo group on any of the measures assessed. Treatment effects were mediated by improvement in depressive symptoms measured on the Child Depression Rating Scale-Revised. CONCLUSIONS: The combination of fluoxetine and CBT was effective in improving functioning, global health, and quality of life in depressed adolescents. Fluoxetine monotherapy improved functioning. Copyright 2006

AB - OBJECTIVE: To test whether 12-week treatment of major depression improved the level of functioning, global health, and quality of life of adolescents. METHOD: The Treatment for Adolescents With Depression Study was a multisite, randomized clinical trial of fluoxetine, cognitive-behavioral therapy (CBT), their combination (COMB), or clinical management with placebo in 439 adolescents with major depression. Functioning was measured with the Children's Global Assessment Scale (CGAS), global health with the Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA), and quality of life with the Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q). Random-effects regression models were applied to the data. RESULTS: Compared with placebo, COMB was effective on the CGAS (p < .0001), HoNOSCA (p < .05), and PQ-LES-Q (p < .001), whereas fluoxetine was superior to placebo on the CGAS only (p < .05). COMB was superior to fluoxetine on the CGAS (p < .05) and PQ-LES-Q (p = .001). Fluoxetine was superior to CBT on the CGAS (p < .01). CBT monotherapy was not statistically different from the placebo group on any of the measures assessed. Treatment effects were mediated by improvement in depressive symptoms measured on the Child Depression Rating Scale-Revised. CONCLUSIONS: The combination of fluoxetine and CBT was effective in improving functioning, global health, and quality of life in depressed adolescents. Fluoxetine monotherapy improved functioning. Copyright 2006

KW - Depression

KW - Functioning

KW - Impairment

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=33845410571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845410571&partnerID=8YFLogxK

U2 - 10.1097/01.chi.0000242229.52646.6e

DO - 10.1097/01.chi.0000242229.52646.6e

M3 - Article

VL - 45

SP - 1419

EP - 1426

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 12

ER -